mouse embryonic fibroblast conditioned medium (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
93
Structured Review
R&D Systems
mouse embryonic fibroblast conditioned medium
Mouse Embryonic Fibroblast Conditioned Medium, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 59 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+embryonic+fibroblast+conditioned+media/Mouse+Embryonic+Fibroblast+(MEF)+Conditioned+Media/pm41985336-70-15-29
Average 93 stars, based on 59 article reviews
Mouse Embryonic Fibroblast Conditioned Medium, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 59 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+embryonic+fibroblast+conditioned+media/Mouse+Embryonic+Fibroblast+(MEF)+Conditioned+Media/pm41985336-70-15-29
Average 93 stars, based on 59 article reviews
mouse embryonic fibroblast conditioned medium - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
Selection:Article Title: hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10 mg/mL of bFGF (GIBCO), 1 mL/mL of Human iPS Reprogramming Boost Supplement II, 10003 (MerckMillipore) and Article Title: An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10μg/ml of bFGF (GIBCO), 1μl/ml of Human iPS Reprogramming Boost Supplement II, 1000x (Merck Millipore) and Article Title: hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10 μg/mL of bFGF (GIBCO), 1 μL/mL of Human iPS Reprogramming Boost Supplement II, 1000× (Merck Millipore) and Transfection:Article Title: hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10 mg/mL of bFGF (GIBCO), 1 mL/mL of Human iPS Reprogramming Boost Supplement II, 10003 (MerckMillipore) and Article Title: An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10μg/ml of bFGF (GIBCO), 1μl/ml of Human iPS Reprogramming Boost Supplement II, 1000x (Merck Millipore) and Article Title: hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10 μg/mL of bFGF (GIBCO), 1 μL/mL of Human iPS Reprogramming Boost Supplement II, 1000× (Merck Millipore) and Laser Capture Microdissection:Article Title: hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10 mg/mL of bFGF (GIBCO), 1 mL/mL of Human iPS Reprogramming Boost Supplement II, 10003 (MerckMillipore) and Article Title: An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10μg/ml of bFGF (GIBCO), 1μl/ml of Human iPS Reprogramming Boost Supplement II, 1000x (Merck Millipore) and Article Title: hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia Article Snippet: Low passage stroma cells seeded at a density of 18,500 cells/cm2 were transfected using SimpliconTM RNA Reprogramming Kit, OKSG (Merck Millipore) following pre-treatment with B18R protein. .. Following puromycin selection over an 8 day period, cells were subjected to 10 μg/mL of bFGF (GIBCO), 1 μL/mL of Human iPS Reprogramming Boost Supplement II, 1000× (Merck Millipore) and Cell Culture:Article Title: Substrate Stiffness, Cell Anisotropy, and Cell-Cell Contact Contribute to Enhanced Structural and Calcium Handling Properties of Human Embryonic Stem Cell-Derived Cardiomyocytes. Article Snippet: Subscriber access provided by UNIV OF NEW ENGLAND ARMIDALE is published by the American Chemical Society.. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society.. Copyright © American Chemical Society. |